 | | Vol. 14.48 – 15 December, 2023 |
| |
|
|
| The effect of ADP-dependent glucokinase expression on prostate cancer cell malignant phenotypes was validated in vitro and in vivo.
[Military Medical Research] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Prostate cancer-endothelial cell interactions were investigated, after coculture, by flow cytometry, transcriptional profiling, western blot, and ELISA assays.
[Journal Of Experimental & Clinical Cancer Research] |
|
|
|
| The authors showed that miR-96-5p, miR-183-5p and miR-210-3p were specifically released by docetaxel resistant prostate cancer clones, and decreased the efficacy of docetaxel in prostate cancer cells when overexpressed.
[Cell Death Discovery] |
|
|
|
| Investigators established an iRFP stable expression CRPC cell line suitable for deep-tissue observation using fluorescence molecular tomography, and these cells were implanted into murine prostate tissue.
[Cancer Gene Therapy] |
|
|
|
| Scientists tested whether modifying carbohydrate quality to lower glycemic index, without changing quantity, resulted in similar benefits as with reduced quantityl, in the context of prostate cancer growth.
[Prostate Cancer And Prostatic Diseases] |
|
|
|
| Daily deuterium oxide administration was combined with the collection of plasma, skeletal muscle, non-tumorous prostate, and prostate tumor tissue during the surgical procedure to determine tissue protein synthesis rates throughout the intervention period.
[Medical Science in Sports & Exercise] |
|
|
|
| Investigators found that the positive expression rate of NSD2 increased progressively in benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and prostate cancer.
[Scientific Reports] |
|
|
|
| Human prosate cancer cell lines were treated with the prodrug DRP-104 and effects on proliferation and cell death were assessed.
[Prostate] |
|
|
|
| The animal experiment component induced experimental autoimmune prostatitis in non-obese diabetic mice through intradermal prostate antigen injection and complete Freund’s adjuvant.
[Prostate] |
|  |
|
|
|
| Scientists provide an overview of the unique signaling and metabolic pathways of CSCs, summarize existing CSC biomarkers and CSC-targeted therapies, and discuss strategies to further differentiate CSCs from non-stem cancer cells.
[Trends In Pharmacological Sciences] |
|
|
|
|
| Two Monash Biomedicine Discovery Institute early career researchers have been awarded two of Cancer Council Victoria’s four annually awarded Postdoctoral Research Fellowships, Dr. Porter’s project seeks to harness the power of the immune system to fight prostate cancer through CAR T cell therapy.
[Monash University] |
|
|
|
|
| February 21 – 24, 2024
San Antonio, Texas, United States |
|
|
|
|
|
| | Pfizer – Multiple Locations, United States |
|
|
|
| | Albert Einstein College of Medicine – Bronx, New York, United States |
|
|
|
| | Institut Necker Enfants Malades – Paris, France |
|
|
|
| | Cedars-Sinai – Los Angeles, California, United States |
|
|
|
| | Cedars-Sinai – Los Angeles, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
